Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer

• Published in: Cancers Vol. 13; no. 7; p. 1588
• Main Authors: De Laere, Bram, Crippa, Alessio, Mortezavi, Ashkan, Ghysel, Christophe, Rajan, Prabhakar, Eklund, Martin, Wyatt, Alexander, Dirix, Luc, Ost, Piet, Grönberg, Henrik, Lindberg, Johan, On Behalf Of The Core And ProBio Investigators
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.03.2021; MDPI
• Subjects: Acetic acid; Androgen receptors; biomarker; Biomarkers; Cancer therapies; Castration; Cell cycle; cfDNA; Chemotherapy; Clinical trials; Datasets; Deoxyribonucleic acid; DNA; DNA fingerprinting; DNA repair; Estimates; Genes; Genomics; mCRPC; Medical prognosis; Medicin och hälsovetenskap; Metastases; Metastasis; Oncology; Patients; Plasma; Prognosis; Prostate cancer; Regression analysis; Signal transduction; Tumors; mCRPC; biomarker; cfDNA
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13071588

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease, characterized by common and rare driver gene alterations that provide a selective growth advantage for progressing tumour cells. We hypothesized that the number of distinct gene driver alteration-affected pathways or gene classes was associated with poor prognosis in patients initiating androgen receptor signalling inhibitors (ARSi). We performed a post hoc analysis of an amalgamated baseline circulating tumour DNA (ctDNA) mutational landscape dataset of ARSi-treated men with mCRPC ( = 342). We associated the detected hotspot, pathogenic, and/or high impact protein function-affecting perturbations in 39 genes into 13 pathways. Progression-free (PFS) and overall survival (OS) were analysed using Kaplan-Meier curves and multivariate Cox regression models. Driver gene alterations were detected in 192/342 (56.1%) evaluable patients. An increased number of affected pathways, coined pathway complexity index (PCI), resulted in a decremental PFS and OS, and was independently associated with prognosis once ≥3 pathway or gene classes were affected (PFS HR (95%CI): 1.7 (1.02-2.84), = 0.04, and OS HR (95%CI): 2.5 (1.06-5.71), = 0.04). Additionally, visceral disease and baseline PSA and plasma ctDNA levels were independently associated with poor prognosis. Elevated PCI is associated with poor ARSi outcome and supports comprehensive genomic profiling to better infer mCRPC prognosis.